Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALO, ISR, FCRD, SESN

PR Newswire October 28, 2022

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Sesen Bio, Inc. - SESN

PR Newswire October 27, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OCSL, SESN, ISR

PR Newswire September 30, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBET, RMED, OCSL, SESN

PR Newswire September 22, 2022

SESEN BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sesen Bio, Inc. - SESN

Business Wire September 21, 2022

SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders

Business Wire September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

Business Wire September 21, 2022

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

Business Wire August 8, 2022

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum(TM) in the US

Business Wire July 18, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sesen Bio, Inc.

Newsfile May 18, 2022

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

Business Wire May 9, 2022

Sesen Bio Provides Strategic Update

Business Wire May 3, 2022

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company's Lead Product Candidate, Vicineum(TM)

Business Wire February 28, 2022

Sesen Bio Further Enhances Team with Key Hires

Business Wire January 10, 2022

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum(TM)

Business Wire December 9, 2021

Sesen Bio Strengthens Medical Team

Business Wire November 29, 2021

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

Business Wire November 23, 2021

Sesen Bio Reports Third Quarter 2021 Financial Results and Business Update

Business Wire November 8, 2021

Sesen Bio Announces Productive CMC Type A Meeting with the FDA

Business Wire November 1, 2021

CLASS ACTION UPDATE for SESN, HYRE and SAM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Accesswire October 18, 2021